U.S. FDA set to rule on controversial Biogen Alzheimer's drug
By Deena BeasleyJune 7 (Reuters) - The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's aducanumab, a decision that will affect...
By Deena BeasleyJune 7 (Reuters) - The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's aducanumab, a decision that will affect...